Business Wire 7-Dec-2018 6:33 PM
Celcuity Inc. (NASDAQ:CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced that it presented results from three studies of the CELx MP Signaling Function Test at the 2018 San Antonio Breast Cancer Symposium on December 6, 2018.
The CELx MP test identifies a significant subset of HER2-negative breast cancer patients with coincidental hyperactive c-Met and HER family signaling tumors that respond ex vivo to a combination of pan-HER and c-Met tyrosine kinase inhibitors. These studies characterize the CELx MP Test's analytical performance and provide a demonstration of the pathogenicity of coincidental hyperactive HER-family and c-Met signaling in HER2-negative breast cancer tumors using an animal model.
Posters and primary results included:
Copies of the abstracts and posters Celcuity presented at the 2018 San Antonio Breast Cancer Symposium can be found at www.celcuity/publications
About CelcuityCelcuity Inc. is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Celcuity's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy that can best treat that patient's disease. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.
Forward-Looking StatementsThis press release and the abstracts and posters referred to herein contain statements that constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "should," "suggests," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends" or "continue," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward looking statements in this release and the abstracts and posters referred to herein include, without limitation, expectations with respect to the responsiveness of cancer patients with certain cell signaling to certain inhibitors (or combinations thereof), beliefs regarding the ability to minimize drug toxicities without impacting efficacy of treatment and beliefs regarding the merits of conducting additional clinical trials to evaluate responsiveness of certain cancer patient subsets to certain inhibitors. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, those set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 15, 2018. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.